Concepedia

Kerstin Allen

KA

Statistics

Publications

15

Citations

977

H-Index

13

Active since

1990

Affiliations

Infinity Pharmaceuticals (United States)(Current)

Sarah Cannon

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Yale Cancer Center

Kerstin Allen is an author at Infinity Pharmaceuticals (United States) specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

1990–2018

15

Publications

15

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Steven M. Horwitz, Raphael Koch, Pierluigi Porcu et al. · Blood · 2017 · 283 citations · Full text

, , +7

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad S. Kahl et al. · Blood · 2017 · 253 citations · Full text

, , +10

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Susan O’Brien, Manish R. Patel, Brad S. Kahl et al. · Blood · 2014 · 65 citations

, , +10

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Susan O’Brien, Manish R. Patel, Brad S. Kahl et al. · American Journal of Hematology · 2018 · 58 citations · Full text

, , +17

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian W. Flinn, Yasuhiro Oki, Manish R. Patel et al. · Blood · 2014 · 48 citations

, , +5

1–5 of 15